244 related articles for article (PubMed ID: 21850662)
21. Clonal chromosome aberrations in Philadelphia-negative cells from chronic myelocytic leukemia patients treated with imatinib mesylate: report of two cases.
Herens C; Baron F; Croisiau C; Tassin F; Bours V
Cancer Genet Cytogenet; 2003 Nov; 147(1):78-80. PubMed ID: 14580776
[TBL] [Abstract][Full Text] [Related]
22. Allogeneic transplantation: a therapeutic option for myelofibrosis, chronic myelomonocytic leukemia and Philadelphia-negative/BCR-ABL-negative chronic myelogenous leukemia.
Mittal P; Saliba RM; Giralt SA; Shahjahan M; Cohen AI; Karandish S; Onida F; Beran M; Champlin RE; de Lima M
Bone Marrow Transplant; 2004 May; 33(10):1005-9. PubMed ID: 15048141
[TBL] [Abstract][Full Text] [Related]
23. Chronic myeloid leukaemia: The dangers of not knowing your BCR-ABL1 transcript.
Sharplin K; Altamura H; Taylor K; Wellwood J; Taylor D; Branford S
Leuk Res; 2019 Dec; 87():106231. PubMed ID: 31639634
[No Abstract] [Full Text] [Related]
24. Development and progression of a Philadelphia-chromosome-negative acute myelocytic leukemia clone in a patient with Philadelphia-chromosome-positive chronic myelocytic leukemia.
Cullen MJ; Richards SJ; Dickinson H; Carter C; Swirsky DM; Owen RG
Cancer Genet Cytogenet; 2004 Jan; 148(2):170-3. PubMed ID: 14734234
[TBL] [Abstract][Full Text] [Related]
25. NT157, an IGF1R-IRS1/2 inhibitor, exhibits antineoplastic effects in pre-clinical models of chronic myeloid leukemia.
Scopim-Ribeiro R; Machado-Neto JA; Eide CA; Coelho-Silva JL; Fenerich BA; Fernandes JC; Scheucher PS; Savage Stevens SL; de Melo Campos P; Olalla Saad ST; de Carvalho Palma L; de Figueiredo-Pontes LL; Simões BP; Rego EM; Tognon CE; Druker BJ; Traina F
Invest New Drugs; 2021 Jun; 39(3):736-746. PubMed ID: 33403501
[TBL] [Abstract][Full Text] [Related]
26. Clinical significance of reverse BCR/ABL gene rearrangement in Ph-negative chronic myelogenous leukemia.
Verma RS; Chandra P
Leuk Res; 2000 Jul; 24(7):631-5. PubMed ID: 10867140
[No Abstract] [Full Text] [Related]
27. Juvenile chronic myeloid leukaemia and alpha-interferon.
Aricò M; Nespoli L; Caselli D; Bonetti F; Porta FA; Burgio GR
Eur J Pediatr; 1989 Jan; 148(4):379-80. PubMed ID: 2707286
[No Abstract] [Full Text] [Related]
28. [Chronic myeloid leukemia. Diagnosis, development and prognosis].
Tanzer J
Rev Prat; 1988 Jun; 38(18):1210-6. PubMed ID: 3175491
[No Abstract] [Full Text] [Related]
29. Duplication of chromosome 9 carrying a BCR/ABL chimeric gene in Philadelphia chromosome negative chronic myeloid leukemia.
Takahashi N; Miura I; Ohshima A; Utsumi S; Nimura T; Hashimoto K; Saito M; Miura AB
Cancer Genet Cytogenet; 1996 Jul; 89(2):166-9. PubMed ID: 8697426
[TBL] [Abstract][Full Text] [Related]
30. ABL gene fuses BCR during t(20;22) results in Philadelphia-negative, but BCR/ABL-positive chronic myeloid leukemia.
Ito Y; Shimamoto T; Kuriyama Y; Nakajima A; Sumi M; Watanabe Y; Beppu H; Ohtsubo K; Ohyashiki K
Leukemia; 2002 May; 16(5):951-2. PubMed ID: 11986960
[No Abstract] [Full Text] [Related]
31. Imatinib independent aberrant methylation of NOV/CCN3 in chronic myelogenous leukemia patients: a mechanism upstream of BCR-ABL1 function?
Vatanmakanian M; Tavallaie M; Ghadami S
Cell Commun Signal; 2019 Apr; 17(1):38. PubMed ID: 31014357
[TBL] [Abstract][Full Text] [Related]
32. Introduction to 'A special spotlight review series on BCR-ABL-negative myeloproliferative neoplasms'.
Tefferi A; Constantinescu SN
Leukemia; 2008 Jan; 22(1):1. PubMed ID: 18197171
[No Abstract] [Full Text] [Related]
33. Co-existence of
Frikha R; Turki F; Kassar O; Elloumi M; Kamoun H
J Oncol Pharm Pract; 2021 Oct; 27(7):1784-1789. PubMed ID: 33567976
[TBL] [Abstract][Full Text] [Related]
34. Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR-ABL1 and its resistance and compound mutants BCR-ABL1
Mian AA; Haberbosch I; Khamaisie H; Agbarya A; Pietsch L; Eshel E; Najib D; Chiriches C; Ottmann OG; Hantschel O; Biondi RM; Ruthardt M; Mahajna J
Ann Hematol; 2021 Aug; 100(8):2023-2029. PubMed ID: 34110462
[TBL] [Abstract][Full Text] [Related]
35. The use of Imatinib resistance mutation analysis to direct therapy in Philadelphia chromosome/BCR-ABL1 positive chronic myeloid leukaemia patients failing Imatinib treatment, in Patan Hospital, Nepal.
Kayastha GK; Ranjitkar N; Gurung R; Kc RK; Karki S; Shrestha R; Rajbhandari P; Thapa RK; Poudyal B; Acharya P; Roberts DJ; Hayes B; Zimmerman M; Basnyat B
Br J Haematol; 2017 Jun; 177(6):1000-1007. PubMed ID: 28467002
[TBL] [Abstract][Full Text] [Related]
36. Philadelphia negative BCR-ABL positive chronic myeloid leukemia mimicking juvenile chronic myeloid leukemia in a 2-year-old child.
Mahon FX; Labouyrie E; Aurich-Costa J; Dastugue N; Micheau M; Bady C; Perel Y; Bilhou-Nabera C; Reiffers J; Bernard P
Leuk Lymphoma; 1997 Aug; 26(5-6):615-9. PubMed ID: 9389369
[TBL] [Abstract][Full Text] [Related]
37. Detection of BCR-ABL1 kinase domain mutations causing imatinib resistance in chronic myelogenous leukemia.
Moore FR; Yang F; Press RD
Methods Mol Biol; 2013; 999():25-39. PubMed ID: 23666688
[TBL] [Abstract][Full Text] [Related]
38. Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia.
Soverini S; Branford S; Nicolini FE; Talpaz M; Deininger MW; Martinelli G; Müller MC; Radich JP; Shah NP
Leuk Res; 2014 Jan; 38(1):10-20. PubMed ID: 24131888
[TBL] [Abstract][Full Text] [Related]
39. BCR-ABL1 compound mutations drive ponatinib resistance.
Cancer Discov; 2014 Nov; 4(11):OF13. PubMed ID: 25367954
[TBL] [Abstract][Full Text] [Related]
40. Translocation of BCR to chromosome 9 in a Philadelphia-negative chronic myeloid leukemia.
Brunel V; Sainty D; Costello R; Mozziconacci MJ; Simonetti J; Arnoulet C; Coignet L; Bouabdallah R; Gastaut JA; Gabert J
Cancer Genet Cytogenet; 1995 Nov; 85(1):82-4. PubMed ID: 8536245
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
